BLOG / 🇮🇳 India / index intelligence · · daily

BSE Pharma Sector Regulatory Filings — July 30, 2026

India BSE PHARMA

By Gunpowder Editorial ·

4 high priority 12 medium priority 16 total filings analysed

Executive Summary

The India BSE PHARMA digest for July 30, 2026, reveals a sector bifurcated between strong operational performance and emerging risk factors. Mankind Pharma and Torrent Pharmaceuticals reported robust revenue growth (12.9% YoY and 55% YoY respectively), driven by domestic chronic therapy demand and M&A benefits, with Mankind showing margin expansion.

However, Torrent's net profit growth lagged significantly due to merger-related exceptional items, and its Germany business declined. Max Healthcare continues its expansion trajectory, aiming to double bed capacity, but saw notable institutional dissent on director re-appointments. A key sector theme is the divergence between revenue growth and profitability, with M&A integration costs and supply disruptions creating headwinds. Insider activity was absent across all filings, limiting conviction signals. The forward-looking catalyst calendar is active, with Zydus Lifesciences' Q1 results and earnings call on August 11 being the next major event. Overall, the sector shows healthy demand but requires careful stock selection to navigate margin pressures and integration risks.

Materiality, sentiment, and priority are scored by Gunpowder’s analysis pipeline. How we score filings →

Filing types in this digest: Corporate governance

Tracking the trend? Catch up on the prior BSE Pharma Sector Regulatory Filings digest from July 29, 2026.

Investment Signals (10)

  • Mankind Pharma ↓ (BULLISH)
    ▲

    Revenue grew 12.9% YoY to ₹4,031 Cr, with EBITDA margin expanding 250 bps YoY to 26.3% and PAT margin up 170 bps YoY to 14.2%, indicating strong operational leverage and cost control

  • Mankind Pharma ↓ (BULLISH)
    ▲

    Chronic therapies (cardiac +19.4%, anti-diabetes +12.7%) drove domestic business growth of 11% YoY, signaling a durable shift towards high-margin, recurring revenue streams

  • Mankind Pharma ↓ (BULLISH)
    ▲

    Standalone debt-equity ratio improved to 0.25x from 0.48x YoY, and interest coverage ratio more than doubled to 8.61x from 3.89x, reflecting significant deleveraging and improved financial health

  • Torrent Pharmaceuticals ↓ (BULLISH)
    ▲

    Consolidated revenue surged 55% YoY to ₹4,921 Cr, driven by JB Pharma amalgamation and 17% organic growth in the base business, with India business delivering record 19% organic growth

  • Torrent Pharmaceuticals ↓ (BULLISH)
    ▲

    Base business operating EBITDA margin improved to 33.3% from 32.5% YoY, indicating core profitability expansion despite merger-related noise

  • Mankind Pharma ↓ (BULLISH)
    ▲

    Exports surged 29.0% YoY, providing a diversification benefit and reducing dependence on the domestic market

  • Max Healthcare ↓ (BULLISH)
    ▲

    AGM approved all resolutions with >97% support, and the company aims to nearly double bed capacity over five years, signaling aggressive expansion and long-term growth visibility

  • Mankind Pharma ↓ (BEARISH)
    ▲

    Secondary sales growth of 12.7% slightly trailed IPM growth of 13.0% (ex-Trizepatide), indicating a marginal loss of market share in the broader market

  • Torrent Pharmaceuticals ↓ (BEARISH)
    ▲

    Net profit grew only 3% YoY to ₹566 Cr despite 55% revenue growth, weighed down by ₹21 Cr in exceptional items including a fire-related inventory write-off and merger costs

  • Torrent Pharmaceuticals ↓ (BEARISH)
    ▲

    Germany revenues declined 9% in constant currency due to supply disruptions, highlighting vulnerability in international operations

Risk Flags (9)

  • Mankind Pharma/Income Tax Dispute↓ [HIGH RISK]
    ▼

    Ongoing proceedings with aggregate adjustments of ₹1,868.89 Cr (standalone) and ₹1,908.66 Cr (consolidated), with appeals pending before appellate tax authorities, creating significant contingent liability risk

  • Torrent Pharmaceuticals/Profitability Drag↓ [HIGH RISK]
    ▼

    Net profit declined 10.7% YoY on a standalone basis despite 58.9% revenue growth, with exceptional items from a fire incident and merger costs eroding bottom-line gains

  • Torrent Pharmaceuticals/Germany Operations↓ [MEDIUM RISK]
    ▼

    Revenues declined 9% in constant currency due to supply disruptions, a key developed market facing headwinds that could persist

  • Mankind Pharma/Consumer Healthcare Weakness↓ [MEDIUM RISK]
    ▼

    Segment grew only ~4% YoY, partly impacted by discontinuation of cash-and-carry business, underperforming the overall portfolio and indicating strategic challenges

  • Torrent Pharmaceuticals/Brazil Slowdown↓ [MEDIUM RISK]
    ▼

    Constant currency revenues grew only 3% YoY, impacted by one-time channel inventory reduction, suggesting potential demand softness in a key emerging market

  • Mankind Pharma/Market Share Loss↓ [LOW RISK]
    ▼

    Secondary sales growth of 12.7% trailed IPM growth of 13.0% (ex-Trizepatide), indicating slight competitive pressure in the domestic market

  • Torrent Pharmaceuticals/Senior Management Churn↓ [LOW RISK]
    ▼

    Three senior management personnel (Hasmukh Patel, Sushil Jaiswal, Sunil Nadkarni) ceased roles effective July 30 due to reporting structure changes, potentially signaling organizational instability

  • Max Healthcare/Institutional Dissent↓ [LOW RISK]
    ▼

    Public institutional shareholders voted against re-appointment of Director Anil Kumar Bhatnagar (3.1%-3.6% votes against), indicating governance concerns among sophisticated investors

  • Mankind Pharma/Debt Service Coverage Decline↓ [LOW RISK]
    ▼

    Standalone debt service coverage ratio declined to 0.59 from 0.76 YoY, indicating reduced ability to service debt from operating cash flows despite overall deleveraging

Opportunities (9)

  • Mankind Pharma/Margin Expansion↓ (OPPORTUNITY)
    ◆

    Gross margin improved 230 bps YoY to 72.8% and EBITDA margin expanded 250 bps YoY to 26.3%, suggesting pricing power and cost efficiencies that could sustain if chronic therapy growth continues

  • Torrent Pharmaceuticals/Merger Synergies↓ (OPPORTUNITY)
    ◆

    JB Pharma amalgamation is expected to unlock cost and revenue synergies; with base business margins improving to 33.3%, full integration benefits could drive significant earnings upgrades

  • Mankind Pharma/Export Growth↓ (OPPORTUNITY)
    ◆

    Exports surged 29% YoY, providing a growth vector less correlated with domestic competition; continued expansion could re-rate the stock

  • Torrent Pharmaceuticals/India Market Leadership↓ (OPPORTUNITY)
    ◆

    Ranked 1st in IPM cardiac market with India business growing 19% YoY, a high-barrier, high-margin segment that offers sustainable competitive advantage

  • Max Healthcare/Capacity Expansion↓ (OPPORTUNITY)
    ◆

    Aiming to nearly double bed capacity over five years, with acquisition of 58.28% stake in Kalinga Hospital Limited already underway, providing a clear volume-driven growth trajectory

  • Mankind Pharma/Deleveraging Story↓ (OPPORTUNITY)
    ◆

    Debt-equity ratio improved to 0.25x from 0.48x YoY and interest coverage more than doubled, freeing up cash flow for potential dividend increases or further investment

  • Zydus Lifesciences/Upcoming Catalyst↓ (OPPORTUNITY)
    ◆

    Q1 FY27 results and earnings call scheduled for August 11, 2026, with MD Dr. Sharvil Patel hosting; potential for positive surprises given sector momentum

  • Torrent Pharmaceuticals/Acute Recovery↓ (OPPORTUNITY)
    ◆

    Anti-invectives segment grew 3.6% in Q1 FY27 vs -1.1% in Q4 FY26, indicating a turnaround in acute therapies that could further boost domestic growth

  • Mankind Pharma/BSV Integration↓ (OPPORTUNITY)
    ◆

    Corporate guarantee issued for Bharat Serums and Vaccines subsidiary, with prior-period restatement completed, suggesting integration is progressing and could unlock value

Sector Themes (5)

  • Chronic Therapy Dominance (HIGH CONFIDENCE)
    ◆

    Both Mankind Pharma (cardiac +19.4%, anti-diabetes +12.7%) and Torrent Pharmaceuticals (ranked 1st in IPM cardiac market, India business +19%) are seeing outsized growth in chronic therapies, indicating a sector-wide shift towards high-margin, recurring revenue from lifestyle diseases

  • M&A as a Double-Edged Sword (HIGH CONFIDENCE)
    ◆

    Torrent's 55% revenue growth from JB Pharma amalgamation contrasts with only 3% net profit growth due to integration costs, while Mankind's BSV acquisition is still being integrated. M&A is driving top-line expansion but creating near-term earnings dilution and operational complexity

  • Margin Divergence Across Companies (MEDIUM CONFIDENCE)
    ◆

    Mankind Pharma expanded EBITDA margins 250 bps YoY to 26.3%, while Torrent's base business margins improved only 80 bps to 33.3% and net profit declined. This suggests that margin trends are company-specific and depend on M&A stage and therapy mix

  • International Operations Under Pressure (MEDIUM CONFIDENCE)
    ◆

    Torrent's Germany (-9% CC) and Brazil (+3% CC) both underperformed domestic growth, while Mankind's exports (+29%) were a bright spot. This highlights the uneven recovery in global pharma markets and the importance of geographic diversification

  • Capital Allocation Focus on Expansion (MEDIUM CONFIDENCE)
    ◆

    Max Healthcare is doubling bed capacity, Mankind is investing in a Netherlands subsidiary for R&D, and Torrent is integrating JB Pharma. The sector is prioritizing growth capex and M&A over shareholder returns, with no buybacks or special dividends announced

Watch List (1)

Filing Analyses (16)
Aurobindo Pharma Limited Corporate Governance neutral materiality 1/10

30-07-2026

Aurobindo Pharma Limited has informed stock exchanges that it published newspaper notices on July 30, 2026, in Business Standard and Nava Telangana, announcing that its 39th Annual General Meeting (AGM) will be held on August 27, 2026, at 3:30 p.m. IST through Video Conferencing / Other Audio-Visual Means. The filing is a routine corporate governance disclosure and contains no financial results, operational updates, or material business developments.

  • · The AGM will be held on Thursday, August 27, 2026, at 3:30 p.m. IST.
  • · The meeting will be conducted through Video Conferencing / Other Audio-Visual Means.
  • · Notices were published in Business Standard (English) and Nava Telangana (Telugu) newspapers on July 30, 2026.
Mankind Pharma Limited Corporate Governance positive materiality 8/10

30-07-2026

Mankind Pharma reported standalone revenue from operations of ₹2,964.05 Cr for Q1 FY27 (quarter ended June 30, 2026), up 15.3% YoY from ₹2,569.73 Cr in Q1 FY26. Profit after tax rose 34.5% YoY to ₹558.49 Cr from ₹415.27 Cr. However, the company's debt service coverage ratio declined to 0.59 from 0.76 in the prior year quarter, and the board also approved a corporate guarantee for its wholly owned subsidiary Bharat Serums and Vaccines Limited.

  • · The board meeting started at 02:20 PM IST and concluded at 03:10 PM IST on July 30, 2026.
  • · The company issued a corporate guarantee in favor of its wholly owned subsidiary Bharat Serums and Vaccines Limited (BSV).
  • · The auditors drew attention to an uncertainty regarding income tax proceedings initiated under Section 132 of the Income Tax Act, 1961, with an appeal pending before appellate tax authorities.
  • · Comparative figures for Q1 FY26 have been restated to reflect adjustments from the business combination (acquisition of BSV's business undertaking) accounted for during FY26.
  • · Basic EPS for Q1 FY27 was ₹13.53 (not annualized) vs ₹10.06 in Q1 FY26.
  • · Current ratio for Q1 FY27 was 0.84, down from 0.82 in Q1 FY26.
  • · Bad debts to trade receivable ratio remained flat at 0.00 for both periods.
Mankind Pharma Limited Market Notice mixed materiality 8/10

30-07-2026

Mankind Pharma reported Q1 FY27 revenue of ₹4,031 Cr, up 12.9% YoY, with EBITDA margins improving 250 bps to 26.3%. Domestic business (ex-CH) grew 11.0% YoY, driven by double-digit growth in chronic therapies (cardiac +19.4%, anti-diabetes +12.7%) and strong performance in acute segments. However, the Consumer Healthcare segment grew only 3.9% YoY, partly impacted by the discontinuation of cash-and-carry business, and the company's secondary sales growth of 12.7% slightly trailed the IPM growth of 13.0% (ex-Trizepatide).

  • · Q1 FY27 gross margin improved 230 bps YoY to 72.8%.
  • · Q1 FY27 EBITDA margin improved 250 bps YoY to 26.3%.
  • · Q1 FY27 PAT margin improved 170 bps YoY to 14.2%.
  • · Diluted EPS for Q1 FY27 was ₹13.7, up 29.6% YoY.
  • · Cash EPS for Q1 FY27 was ₹19.2, up 20.8% YoY.
  • · Net debt to EBITDA ratio improved to 0.9x as of June 30, 2026 from 1.1x as of March 31, 2026.
  • · ROCE (with BSV acquisition) was 13% for FY26.
  • · Consumer Healthcare segment EBITDA margin was 18.6% in Q1 FY27, down from 19.9% in Q1 FY26.
  • · MT & E-commerce share in CH increased to 15% in Q1 FY27 from 11% in Q1 FY26, supported by 38% growth.
  • · Mankind launched 1 new product in the US in Q1 FY27, taking total launched products to 49.
  • · Share price as of June 30, 2026 was ₹2,546.50 on NSE.
  • · Free float market cap was ₹27,765 Cr as of June 30, 2026.
Mankind Pharma Limited Market Update positive materiality 9/10

30-07-2026

Mankind Pharma reported a strong Q1 FY26 with standalone revenue from operations of ₹2,964.05 Cr, up 15.3% YoY, and consolidated revenue of ₹4,030.59 Cr, up 12.9% YoY. Standalone PAT grew 34.5% YoY to ₹558.49 Cr, while consolidated PAT rose 29.1% to ₹574.09 Cr. However, the company faces ongoing income tax proceedings with aggregate adjustments of ₹1,868.89 Cr (standalone) and ₹1,908.66 Cr (consolidated), against which appeals have been filed. Additionally, the Board approved the divestment of wholly owned subsidiary Broadway Hospitality Services for ₹49 Cr and the incorporation of a Netherlands subsidiary for R&D investments.

  • · Standalone operating margin improved to 31% in Q1 FY26 from 27% in Q1 FY25.
  • · Standalone net profit margin improved to 19% in Q1 FY26 from 16% in Q1 FY25.
  • · Consolidated debt-equity ratio improved to 0.25 times in Q1 FY26 from 0.48 times in Q1 FY25.
  • · Consolidated interest service coverage ratio improved to 8.61 times in Q1 FY26 from 3.89 times in Q1 FY25.
  • · The company acquired the Branded Generic Business (Women's Health Portfolio) of BSV for ₹797 Cr, effective November 1, 2025, accounted as a common control business combination.
  • · Exceptional items of ₹22.82 Cr (standalone) and ₹23.16 Cr (consolidated) in Q4 FY25 related to labour code impact and stamp duty on IP assignment.
  • · The company made investments of ₹17.11 Cr in Mankind Pharma LLC and ₹50 Cr in Mankind Medicare Private Limited during Q1 FY26.
  • · Income tax proceedings remain pending with aggregate adjustments of ₹1,868.89 Cr (standalone) and ₹1,908.66 Cr (consolidated); management believes no material impact on financials.
Mankind Pharma Limited Market Update positive materiality 8/10

30-07-2026

Mankind Pharma reported standalone revenue from operations of ₹2,964.05 Cr for Q1 FY26 (ended June 30, 2026), up 15.3% YoY from ₹2,569.73 Cr in Q1 FY25. Net profit rose 34.5% YoY to ₹558.49 Cr from ₹415.27 Cr. However, the company faces an ongoing income tax dispute and the prior-period figures have been restated due to the BSV business combination, which complicates direct comparability.

  • · The Board also approved issuance of a corporate guarantee in favour of wholly owned subsidiary Bharat Serums and Vaccines Limited (BSV).
  • · The company's debt equity ratio improved to 0.25x from 0.48x a year ago, indicating deleveraging.
  • · Interest service coverage ratio more than doubled to 8.61x from 3.89x YoY.
  • · Net worth increased to ₹16,967.03 Cr from ₹14,763.59 Cr in the prior year.
  • · The auditors highlighted an ongoing income tax dispute (search under Section 132 of Income Tax Act) with an appeal pending before appellate authorities.
  • · Prior period figures have been restated due to the acquisition of the business undertaking of BSV during FY26, affecting comparability.
  • · Basic EPS for Q1 FY26 was ₹13.53 (not annualised) vs ₹10.06 in Q1 FY25.
Mankind Pharma Limited Market Notice positive materiality 8/10

30-07-2026

Mankind Pharma reported strong Q1 FY27 results with revenue of INR 4,031 Cr (up 12.9% YoY), EBITDA of INR 1,060 Cr (up 24.7% YoY), and PAT of INR 574 Cr (up 29.1% YoY). Domestic business (ex-CH) grew 11.0% YoY, led by chronic therapies (cardiac +19.4%, anti-diabetes +12.7%), while exports surged 29.0% YoY. However, the Consumer Healthcare segment grew only ~4% YoY, partly impacted by the discontinuation of cash and carry business, and EBITDA margin declined 10 bps QoQ to 26.3%.

  • · Secondary sales growth of 12.7% vs IPM growth of 13.0% in Q1 FY27
  • · Chronic therapies: cardiac +19.4%, anti-diabetes +12.7%
  • · Acute recovery: anti-invectives grew 3.6% in Q1 FY27 vs -1.1% in Q4 FY26
  • · Consumer Healthcare MT & E-Com share increased to 15% from 11% YoY, supported by 38% growth
  • · Diluted EPS of INR 13.7, up 29.6% YoY
  • · Mankind (excluding BSV) launched 1 new product in US in Q1 FY27, total 49 products in US
  • · Prescription share of 15.2% in domestic market, #1 rank for 9 years (IQVIA Jun-2026)
Torrent Pharmaceuticals Limited Market Update mixed materiality 9/10

30-07-2026

Torrent Pharmaceuticals reported Q1 FY27 consolidated revenue of ₹4,921 Cr, up 55% YoY, driven by the amalgamation of JB Pharma and 17% organic growth in the base business. Net profit after tax grew only 3% YoY to ₹566 Cr, impacted by exceptional items of ₹21 Cr including a fire-related inventory write-off and merger costs. The India business delivered record high organic growth of 19%, while Germany revenues declined 9% in constant currency due to supply disruptions.

  • · Base business Op. EBITDA margin was 33.3% vs 32.5% in Q1 FY26.
  • · India business revenues were ₹2,157 Cr, up 19% YoY; Torrent ranked 1st in IPM cardiac market.
  • · Brazil constant currency revenues (R$ 147 million) grew only 3% YoY, impacted by one-time channel inventory reduction.
  • · US constant currency revenues (US$ 44 million) grew 23% YoY, driven by new launches and one-time opportunities.
  • · Germany constant currency revenues (EUR 29 million) declined 9% YoY due to supply disruption and lower tender offtake.
  • · JB Business India Rx (ex trade generics + contrast media) grew 13% to ₹657 Cr.
  • · JB Business CDMO revenues grew 27% to ₹145 Cr.
  • · Consolidated net profit margin declined to 11.5% from 17.2% in Q1 FY26.
  • · Exceptional items of ₹21 Cr include ₹2 Cr merger costs and ₹19 Cr inventory write-off from fire.
  • · Debt equity ratio (consolidated) improved to 0.82 from 1.76 as at March 31, 2026.
  • · Security cover ratio for debentures was 1.44 times as at June 30, 2026.
Max Healthcare Institute Limited Market Update positive materiality 5/10

30-07-2026

Max Healthcare Institute Limited held its 25th Annual General Meeting on July 30, 2026, where shareholders approved all resolutions including the adoption of financial statements, a final dividend of ₹2 per share (20% of face value), and the re-appointment of directors. The Chairman highlighted strong operational and financial performance in FY 2025-26, the company's inclusion in the NIFTY 50 Index, and expansion initiatives including the acquisition of a 58.28% stake in Kalinga Hospital Limited. No negative or flat performance metrics were disclosed in the filing.

  • · The AGM was conducted via video conference with 160 members present.
  • · All 8 resolutions were passed, including the shifting of the registered office from Maharashtra to Haryana.
  • · The company aims to nearly double its bed capacity over the next five years.
  • · No qualifications or adverse remarks were noted in the Statutory Auditor's Report or Secretarial Auditor's Report for FY 2025-26.
Torrent Pharmaceuticals Limited Corporate Governance mixed materiality 8/10

30-07-2026

Torrent Pharmaceuticals reported standalone revenue from operations of ₹4,158 Cr for Q1 FY26 (quarter ended June 30, 2026), up 58.9% YoY from ₹2,616 Cr in Q1 FY25, driven by the amalgamation of J.B. Chemicals & Pharmaceuticals (JB Pharma) effective January 21, 2026. However, net profit declined 10.7% YoY to ₹492 Cr from ₹551 Cr, impacted by exceptional items including a ₹19 Cr inventory write-off from a fire incident at a former JB Pharma warehouse and ₹2 Cr in merger-related costs. The company also announced that Independent Director Ameera Shah will complete her term on August 1, 2026.

  • · The amalgamation of JB Pharma was accounted using the pooling of interest method with effect from the appointed date of January 21, 2026.
  • · Exceptional items in Q1 FY26 include ₹2 Cr for regulatory/statutory fees related to the JB Pharma merger and ₹19 Cr inventory write-off due to a fire incident at a former JB Pharma warehouse.
  • · The company's listed non-convertible debentures of ₹10,990 Cr as at June 30, 2026 are secured by first ranking exclusive charge over designated account assets and specified trademarks.
  • · Independent Director Ameera Shah will complete her term on August 1, 2026.
  • · The Board meeting commenced at 2:00 pm and concluded at 4:40 pm on July 30, 2026.
Torrent Pharmaceuticals Limited Market Notice neutral materiality 2/10

30-07-2026

Torrent Pharmaceuticals announced that Hasmukh Patel, Sushil Jaiswal, and Sunil Nadkarni have ceased to be part of Senior Management effective July 30, 2026, due to a change in reporting structure. No financial impact or further details were disclosed.

Alkem Laboratories Limited Market Update mixed materiality 3/10

30-07-2026

Alkem Laboratories dispatched letters on 30th July, 2026 to shareholders without registered emails providing the exact web-link and path to access the Annual Report for FY 2025-26 and notice of the 52nd Annual General Meeting scheduled for Thursday, 27th August, 2026 at 11.00 A.M (IST) through VC/OAVM. The update is procedural and improves access (positive), but it also highlights that some shareholders have not registered email addresses (area for improvement).

  • · Dispatch date of letters: 30th July, 2026.
  • · AGM date and time: Thursday, 27th August, 2026 at 11.00 A.M (IST) via VC/OAVM.
  • · Cut-off date for determining shareholders without registered email addresses: Friday, 10th July, 2026.
  • · Website: https://www.alkemlabs.com and exact path for Annual Report 2025-26: https://www.alkemlabs.com/investors/annual-reports.
  • · Contact for investor relations: investors@alkem.com and phone 022 3982 9999.
Max Healthcare Institute Limited Corporate Governance positive materiality 5/10

30-07-2026

Max Healthcare Institute Limited held its 25th Annual General Meeting on July 30, 2026, where all eight resolutions were passed with overwhelming shareholder support. The resolutions included adoption of financial statements, declaration of a final dividend of ₹2 per share (20% of face value), re-appointment of Mr. Anil Kumar Bhatnagar as Director, approval of non-executive director remuneration, and shifting of the registered office from Maharashtra to Haryana. While all resolutions passed with over 97% votes in favour, resolutions involving Mr. Bhatnagar's re-appointment (Items 4 and 6) saw notable dissent from public institutional shareholders, with 3.104% and 3.575% votes against respectively.

  • · Remote e-voting period was July 27-29, 2026, with cut-off date July 23, 2026.
  • · Promoter group holds 23,07,77,699 shares and voted 100% in favour on all resolutions.
  • · Public non-institutions had low participation (13.134% votes polled) but overwhelmingly supported all resolutions.
  • · Resolution 7 (shifting registered office to Haryana) passed with 99.999% votes in favour, only 7,735 votes against.
  • · All resolutions were passed with no promoter/promoter group interest except Resolutions 4 and 6 (Mr. Bhatnagar's re-appointments).
Max Healthcare Institute Limited Corporate Governance positive materiality 3/10

30-07-2026

Max Healthcare Institute Limited held its 25th Annual General Meeting on July 30, 2026, where all 8 resolutions were passed with overwhelming shareholder support. Key approvals included adoption of financial statements for FY 2025-26, a final dividend of ₹2 per share (20% of face value), re-appointment of Mr. Anil Kumar Bhatnagar as director, and approval to shift the registered office from Maharashtra to Haryana. While all resolutions passed with over 97% votes in favour, resolutions involving Mr. Bhatnagar's re-appointment (Items 4 and 6) saw notable dissent from public institutional shareholders, with 3.1% and 3.6% votes against respectively.

  • · Remote e-voting period was July 27-29, 2026; cut-off date was July 23, 2026.
  • · No shareholders (promoter or public) were present in person or through proxy; all attendance was via video conferencing.
  • · Promoter group holds 23,07,77,699 shares and voted 100% in favour on all resolutions.
  • · Public institutional shareholders (69,79,36,779 shares) had 92.86% voting participation on most resolutions.
  • · On Resolution 4, public institutions voted 96.896% in favour and 3.104% against (2,01,17,163 votes against).
  • · On Resolution 6, public institutions voted 96.425% in favour and 3.575% against (2,31,71,655 votes against).
  • · Resolution 7 (office shift to Haryana) passed with near-unanimous support: 99.999% in favour, only 7,735 votes against from public non-institutions.
Zydus Lifesciences Limited Analyst/Investor Meet neutral materiality 3/10

30-07-2026

Zydus Lifesciences Limited announced that its Q1 FY27 (April-June 2026) financial results will be declared on August 11, 2026, followed by a post-results earnings call at 4:00 PM IST hosted by Managing Director Dr. Sharvil Patel. The filing provides logistical details for the call and confirms that the audio recording and transcript will be available on the company's website.

  • · Q1 FY27 results will be declared on Tuesday, August 11, 2026.
  • · Earnings call scheduled for 4:00 PM IST on the same day.
  • · Pre-registration link: https://bit.ly/4w2juWX
  • · Audio recording and transcript will be available at https://www.zyduslife.com/investorzone.
  • · FY26 Annual Report link provided in the filing.
Torrent Pharmaceuticals Limited Analyst/Investor Meet neutral materiality 1/10

30-07-2026

Torrent Pharmaceuticals Limited has informed the stock exchanges that the audio recording of its conference call with analysts and investors regarding the financial results for the quarter ended June 30, 2026, is now available on the company's website. This is a routine regulatory disclosure under SEBI Listing Regulations and does not contain any financial results or performance data.

  • · The audio recording is available at https://www.torrentpharma.com/pdf/investors/Audio_Recording30062026.mp3
  • · The conference call covers financial results for the quarter ended June 30, 2026
  • · This disclosure follows a prior letter dated July 17, 2026
Mankind Pharma Limited Analyst/Investor Meet neutral materiality 1/10

30-07-2026

Mankind Pharma Limited has informed the exchanges that the audio recording of its Q1FY27 investor conference call, held on July 30, 2026, is now available on the company's website. This is a routine disclosure under SEBI LODR regulations and does not contain any financial results or material business updates.

  • · The audio recording link is: https://www.mankindpharma.com/wp-content/uploads/2026/07/Mankind-Q1-FY27-Audio.mp3
  • · The prior intimation for the call was dated July 17, 2026.

Get daily alerts with 10 investment signals, 9 risk alerts, 9 opportunities and full AI analysis of all 16 filings

Start free trial Browse all digests

₹500/mo after a 14-day free trial — no credit card required. See pricing or explore intelligence streams.

More from: BSE Pharma Sector Regulatory Filings

July 28, 2026

BSE Pharma Sector Regulatory Filings — July 28, 2026

July 27, 2026

BSE Pharma Sector Regulatory Filings — July 27, 2026

July 25, 2026

BSE Pharma Sector Regulatory Filings — July 25, 2026

July 24, 2026

BSE Pharma Sector Regulatory Filings — July 24, 2026

🇮🇳 More from India

View all →

July 31, 2026

India Pre-Market Regulatory Roundup — July 31, 2026

India Pre-Market Regulatory Roundup

July 31, 2026

India Quarterly Results BSE NSE Announcements — July 31, 2026

India Quarterly Results BSE NSE Announcements

July 31, 2026

India Upcoming Corporate Actions BSE NSE — July 31, 2026

India Upcoming Corporate Actions BSE NSE

July 31, 2026

India Merger Acquisition MCA Regulatory Filings — July 31, 2026

India Merger Acquisition MCA Regulatory Filings
← All India digests